Kayothera

Kayothera specializes in inhibiting two of the last remaining nuclear receptors pathways to be drugged – the retinoid and rexinoid nuclear receptors. These pathways are clinically validated to drive adverse cardiometabolic and cancer outcomes, yet have no available inhibitors – until now. Kayothera’s unique approach blocks the formation of the retinoid or rexinoid nuclear ligands with novel, orally-available small molecules that have proven to be safe and effective medicines. We are developing these medicines to provide patients with new options for managing diabetes, obesity and cancer.